Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics Inc. (ANGO) develops minimally invasive medical devices for oncology, vascular, and surgical treatments. This page aggregates official news and press releases about product innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study results, and market expansions. Content spans earnings announcements, technology partnerships, and FDA clearances relevant to interventional radiology and cancer treatment advancements.
All materials are sourced directly from the company and reputable financial publications. Bookmark this page for structured access to ANGO's evolving role in medical device innovation without promotional bias.
AngioDynamics, a medical technology company, will report its fiscal 2024 fourth-quarter and full-year financial results on July 16, 2024, before market open. The company focuses on restoring blood flow in the vascular system, expanding cancer treatments, and improving patient quality of life. A conference call to discuss the results will be held at 8:00 a.m. ET on the same day. Dial-in options are available for both domestic and international participants, and the call will be webcast on the AngioDynamics investor website. A replay will be accessible online and via phone until July 23, 2024.
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher prevalence compared to the U.S. In December 2023, AngioDynamics completed patient enrollment for its U.S.-based APEX-AV trial, which showed significant decreases in RV/LV ratios and clot burdens, with a low Major Adverse Event rate.
AngioDynamics, Inc. presented results from the APEX-AV trial assessing the AlphaVac F1885 System for pulmonary embolism treatment at SCAI 2024 Scientific Sessions. The trial showed significant improvement in right ventricular function, clot burden reduction, and low Major Adverse Event rate. The FDA clearance of the device marks a milestone in interventional medicine.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
